Document is current
Any future updates will be listed below
-
Authors
Zadik, Yehuda https://orcid.org/0000-0002-6062-6529
Raber-Durlacher, Judith E.
Epstein, Joel B.
Majorana, Alessandra
Miranda-Silva, Wanessa
Yang, Sujin
Blijlevens, Nicole
Elad, Sharon
-
Funding
Funding for this research was provided by:
Hebrew University of Jerusalem
- License Information
-
More Information
Article History
Received: 8 June 2025
Accepted: 6 August 2025
First Online: 13 September 2025
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: Y Zadik, A Majorana, W Miranda-Silva, S Yang, N Blijlevens, and S Elad reported no relevant financial or non-financial interests to disclose. JE Raber-Durlacher received in kind support from Thor Photomedicine Ltd. JE Raber-Durlacher is also Deputy Associate Editor of Supportive Care Cancer. JB Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, Neilsen Inc. JB Epstein is also the Associate Editor-in-Chief for Supportive Care in Cancer.
: The MASCC/ISOO OCSG Statements have been developed to facilitate the expert-opinion based management of oral complications of cancer therapy where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. The Statement authors and the MASCC/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.
